LABORATORY STUDY

Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation

Lin Ruan\textsuperscript{a,b,c}, Xiaoguang Yao\textsuperscript{d}, Wen Li\textsuperscript{c}, Lihong Zhang\textsuperscript{c}, Hongxia Yang\textsuperscript{a,b}, Jiahuan Sun\textsuperscript{b} and Aiying Li\textsuperscript{a,b}

\textsuperscript{a}Department of Biochemistry and Molecular Biology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China; \textsuperscript{b}Hebei key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, Shijiazhuang, Hebei, China; \textsuperscript{c}Nephrology Department, Hebei Medical University First Hospital, Shijiazhuang, Hebei, China; \textsuperscript{d}Surgery Department, College of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang

ABSTRACT

Objective: This study sought to investigate the effect of local expression of galectin-3 in the development of stenotic arteriovenous fistula (AVF).

Methods: We collected stenotic venous tissues, adjacent nonstenotic venous tissues, and blood samples from end-stage renal disease (ESRD) patients with AVF stenosis, while normal venous tissues and blood samples were collected from ESRD patients before AVF creation as controls. Also blood samples were collected from ESRD patients with nonstenosis functional AVF. Galectin-3, proliferating cell nuclear antigen (PCNA), matrix metalloproteinase-9 (MMP-9), and \(\alpha\)-SMA expression in the venous tissues were examined by immunohistochemistry, and the ERK1/2 pathway activity in the intima was accessed by western blot. Serum galectin-3 level was measured by ELISA. Thereafter, human pulmonary arterial smooth muscle cells (HPASMCs) were cultured \textit{in vitro}, and the interaction between Galectin-3 and ERK1/2 pathway in HPASMCs was estimated by western blot.

Results: ESRD patients with stenotic AVF had a significant higher serum galectin-3 level than normal controls, and patients with non-stenotic functional AVF. The expression levels of galectin-3, phosphorylated ERK1/2, PCNA, MMP-9, and \(\alpha\)-SMA in the stenotic venous tissues were higher than that in the normal venous tissues or the adjacent nonstenotic AVF venous tissues. Correlation analysis showed that the expression of galectin-3 of the neointima was positively correlated with PCNA and \(\alpha\)-SMA in the stenotic AVF venous tissues. In HPASMCs, galectin-3 can increase the activity of phosphorylated ERK1/2 and promote the expression of \(\alpha\)-SMA.

Conclusion: In the stenotic AVF of ESRD patients, expression of the galectin-3 was significantly increased, showing a positive relation with neointima development.

ARTICLE HISTORY

Received 28 September 2020
Revised 1 March 2021
Accepted 6 March 2021

KEYWORDS
Galectin; stenosis; arteriovenous fistula; neointima; hemodialysis

Introduction

In 2015, there were an estimated 2.62 million people with end-stage renal disease (ESRD) worldwide, and most patients received hemodialysis treatment as renal replacement therapy [1], in which a well-functioning vascular access is required. According to KDOQI clinical practice guidelines and clinical practice recommendations [2], autologous arteriovenous fistula (AVF) is a preferred vascular access for hemodialysis with a lower all-cause mortality [3]. However, dysfunction remains as the main problem of AVF failure, including venous stenosis formation and lack of maturation. Researchers have estimated AVF patency rates as 62% at 1 year and 40% at 2 years [4–6]. Histologic analysis of stenotic vein specimens reveals neointimal hyperplasia located within the intima of the vessel. Several related signal pathways contributed to the neointima pathology, such as infiltration of inflammatory cells, injury by AVF surgery, uremia, hypoxia, and hemodynamics [7,8], all of which would induce the smooth muscle cells, macrophage, and monocyte migration into the intima of vessels. During the pathology of the neointimal hyperplasia of AVF, the smooth muscle cells could differentiate into myofibroblasts, which then migrate from media into intima and proliferate, eventually resulting in neointimal hyperplasia, extracellular matrix deposition, reduced vascular cavity, and outflow obstruction in AVF tissues [9].
MEK/ERK1/2 pathway belongs to a family of serine/threonine kinase and is a classic pathway in regulation of cell proliferation and migration. A MAPK kinase (MEK) is required for the ERK1/2 phosphorylation of both threonine and tyrosine residues [10], and the activated form of ERK1/2 transmits extracellular stimuli by phosphorylating a variety of substrates, including transcription factors and kinases. Moreover, some study has observed the upregulated activity of MEK/ERK1/2 pathway of smooth muscle cells in the neointima [11], which could contribute to vascular smooth muscle cell contraction, proliferation, migration, differentiation, adhesion, collagen deposition, and survival [12].

Galectins (Gal) belong to a family of β-galactoside-binding lectins with evolutionary conserved carbohydrate recognition domain, and there are 15 galectins identified in vertebrates and expressed in various tissues and organs [13]. Human Gal-3 is a chimera-type galectin, a 35-kDa protein encoded by LGALS3 gene on chromosome 14. Gal-3 expression can be identified in the cytoplasm and nucleus and secreted into microenvironment. It then plays a role in cell proliferation, adhesion, migration, inflammation, and angiogenesis [14,15]. Moreover, Gal-3 can regulate the activity of ERK/ERK1/2 pathway. Fernández et al. suggested that Gal-3 can increase the activity of ERK pathway, through promoting p38 phosphorylation in human neutrophil cells [16], while Chen et al. suggested that Galectin-3 can increase p-ERK phosphorylation level in endothelial cells [17].

Therefore, we speculate that Gal-3 may participate in the pathology of neointima development and then contribute to the AVF stenosis. In this study, we investigated the Gal-3 expression level in the human AVF stenotic vein tissues.

Materials and methods

Subject cohort

Study protocols involving human subjects were approved by the First Hospital of Hebei Medical University institutional ethics committee (20190303, Chinese Clinical Trial Registry No. ChiCTR1900021975). All methods were performed in accordance with the relevant guidelines and regulations. All subjects were ESRD patients who were recruited to receive AVF creation surgery for the first time or received surgery revision due to AVF stenosis between March 2018 and January 2021 (including group1: ESRD patients with stenotic AVF, group2: ESRD patients with functional non-stenotic AVF, group3: ESRD patients who planned to receive AVF surgery (normal controls). All the involved patients agreed to the study and signed written consent forms on their behalf. All the patients received hemodialysis immediately after being diagnosed with ESRD.

The inclusion criteria of this study included (1) age between 18-80 and (2) forearm AVF surgery. The exclusion criteria of the study included (1) systemic infection, (2) heart failure, (3) history of hormone or immunosuppressant therapy during the past of 6 months, (4) pregnancy within 1 month after tissues were collected, and (5) failure to obtain the written consent forms.

The venous tissues were collected during the surgery. For the patients who diagnosed with AVF stenosis at anastomotic site, we collected stenotic venous tissues and non-stenotic venous tissue at 2 cm upstream of stenosis. For the patients who received the first AVF surgery, we collected normal venous tissues before AVF creation as normal controls who had no surgical history on the AVF location previously.

Meanwhile, 5-mL blood was collected from all involved subjects for further investigation. All the collected tissues were stored at −80°C for further experiments.

The criteria of AVF stenosis were as follows: (1) the diameter of vein cavity was decreased more than 50% compared to upstream vein; (2) the ratio of the peak systolic velocity (PSV) of blood flow at this stenosis site to that at 2 cm upstream veins exceeded 3.0, when the stenosis site was within 2 cm of the anastomosis, or exceeded 2.0, when the location was more than 2 cm of the anastomosis; (3) in the outflow stenosis: mid graft PSV < 100 cm/sec, or Distal vein > 300 cm/s; (4) in the inflow stenosis: PSV increased at the site of stenosis with monophasic and diminished waveforms distal, or flow acceleration with graft compression at outflow anastomosis; (5) clinical presentation, unable to cannulate and arm edema [18].

Clinical variables and demographic characteristics were collected from the recruited patients, including age, gender, body mass index (BMI), smoking status, alcohol history, diabetes, serum biochemistry data, duration of dialysis (equal to the duration of ESRD diagnosis), and hypertension history. The data were recorded by the staff of our hospital and analyzed by the researchers involved in this study.

Enzyme-linked immunosorbent assay (ELISA)

Blood samples were collected into serum separator tubes and were left to stand for 2 h at room temperature to clot. The samples were then centrifuged at 1000 × g for 20 min. Thereafter, the supernatants
(serum) were stored at −70 °C until processing. Serum Gal-3 levels and high-sensitivity C-reactive protein (hs-CRP) levels were investigated using the ELISA method with a kit for Gal-3 (R&D Systems, DGAL30) and hs-CRP, respectively (Beyotime biotechnology, PC198, China). Approximately 100-μl samples or standards were added to an antibody-coated 96-well plate, and then 100-μl biotinylated detection antibody (target for Gal-3 or hs-CRP, respectively) was added to the plate and incubated for 1 h at room temperature, following the manufacturer’s instructions. After incubation, the liquid was aspirated, and the wells were washed with phosphate-buffered saline (PBS), and 100-μl streptavidin HP complex reagent was added to the wells and incubated for 1 h at room temperature. Subsequently, 90 μl of TMB substrate solution was added to each well and incubated for 30 min at room temperature. Finally, 50 μl of stop solution was added to each well, and then the absorbance was read at 450 nm using a multimode plate reader. The standard reagents were used to generate a standard curve, and the serum Gal-3 levels were determined based on the standard curve.

**Histological evaluation and immunohistochemistry (IHC)**

The venous tissue was fixed with 10% formalin for 24 h at room temperature and embedded in paraffin. Paraffin-embedded tissue samples were cut into 5-μm-thick sections.

To evaluate histological changes of venous tissue, the slides were stained with hematoxylin and eosin. The stained slides were then examined to confirm the pathology. Also the sections were subjected to two other types of stains: Masson’s trichrome stain (Beyotime, China) and Alizarin Red S stain (Beyotime, China) following the protocols provided.

For IHC, the tissue sections were subsequently deparaffinized with xylene at 55 °C and rehydrated with descending alcohol series and then subjected to antigen retrieval. D Deparaffinized sections were blocked with 5% goat serum (Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Tissue sections were incubated with antibodies (1:200 dilution) against Gal-3, proliferating cell nuclear antigen (PCNA), α-SMA, and matrix metalloproteinase-9 (MMP-9) overnight at 4 °C. Following the primary incubation, sections were incubated with an anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:8000, Abcam, cat. no. ab99702) at room temperature for 1 h. The slides were subsequently stained with 3,3’-diaminobenzidine, counterstained with hematoxylin (0.5%), and visualized using a light microscope (Olympus Corporation). Expression levels were semi-quantified according to the regular IHC staining grade system.

The following antibodies against the target proteins in the study were used: rabbit monoclonal anti-Gal-3 (ab76245, Abcam), rabbit polyclonal anti-PCNA (No. GB11010, Servicebio, USA), rabbit monoclonal anti-α-SMA (#14968, Cell Signaling, USA), rabbit polyclonal anti-MMP-9 (ab38898, Abcam). Negative controls had staining performed with the IgG control, while the positive controls were following the suggestions by the antibodies’ manufacturers.

To analyze the expression level of target protein (Gal-3, α-SMA, PCNA, and MMP-9), images of the entire cross-section (under magnification 5 ×) were obtained using a microscope (Carl Zeiss). Then the results were evaluated using Zen 2.3 digital imaging software (Zeiss), and the positive expression was determined by the appropriate color intensity range in intima, media, and adventitia. Quantified analysis was performed on 12 contiguous sections. The expression indexes were calculated by counting the number of positive cells divided by the total number of cells multiplied by 100 [19].

**Cell culture**

Human pulmonary arterial smooth muscle cells (HPASMCs, catalog no. PCS-100-023) were purchased from the American Type Culture Collection (ATCC).
HPASMCs were cultured at 37°C and 5% CO₂ using DMEM medium (HyClone) and 10% fetal bovine serum (HyClone, USA). Cells were used for subsequent experiments up to passage 4. Antibiotics including penicillin (Beyotime Biotechnology, China) and streptomycin (Beyotime Biotechnology, China) were also used in cell culture.

The cells were treated with Gal-3 (purchased from Sigma, dissolved in PBS) at a concentration of 5 μg/ml [20] and antagonist of ERK1/2 (SCH772984, purchased from Selleck Chemicals) at a concentration of 50 nM in DMSO [21].

Western blotting

Protein extraction from the venous tissues or cell pellets was performed using a total protein extraction kit (Applygen Technologies, China) in accordance with the manufacturer’s protocol. The protein concentrations were determined using a BCA protein assay reagent kit (Novagen). Then, 20 μg of total protein samples was loaded and separated by SDS/PAGE electrophoresis and transferred to PVDF membranes (Millipore Corporation). After blocking with 5% skim milk in TBST buffer (Tris-buffered saline, 0.1% Tween 20) at room temperature for 2 h, the membranes were incubated with the primary antibody (1:3000) at 4°C for 8 h. Thereafter, the membranes were washed with PBS buffer and then incubated with a secondary antibody (1:3000, Abcam, anti-mouse (ab6728), or anti-rabbit (ab205718). Subsequently, the protein level on the blot was detected by Western Bright ECL kit (Bio-Rad Laboratories). The protein level of 18S was applied to validate the equal loading of the samples. The protein expression levels were quantified with ImageJ software (Version 1.8.0), by normalized to the protein level of 18S.

The following antibodies against the target proteins in the study were used: rabbit monoclonal anti-phospho-ERK1/2 (at Thr202/Tyr204, #4370, Cell Signaling), mouse monoclonal anti-ERK1/2 (#4695, Cell Signaling, USA), rabbit monoclonal anti-α-SMA (#14968, Cell Signaling, USA), mouse polyclonal anti-MEK1 (No. GB12304, Servicebio), and rabbit polyclonal anti-18S (No. MBS2520508, MyBioSource).

Statistics

All the data were analyzed in an R environment for statistical computing and graphics (version 3.6.2). Data of clinical variables and demographic characteristics were expressed as the mean ± SD, while the quantitative data

Table 1. Demographic data and clinical variables of involved patients’ cohort.

| Variable                     | Stenosis AVF group | Non-stenosis functional AVF group | Pre AVF surgery group (normal control) | P value |
|------------------------------|--------------------|-----------------------------------|----------------------------------------|---------|
| Patients, n                  | 19                 | 15                                | 42                                     |         |
| Age (years)                  | 53.04 ± 11.51      | 55.06 ± 8.28                      | 51.94 ± 9.94                           | 0.587   |
| Female (%)                   | 9 (47.37)          | 8 (53.33)                         | 19 (45.24)                             | 0.865   |
| Duration of dialysis (m)*    | 34.65 ± 4.74       | 10.93 ± 7.38                      | 2.4 ± 0.77                             | 0.000   |
| Hypertension n (%)           | 15 (78.95)         | 9 (60%)                           | 36 (85.71)                             | 0.111   |
| Diabetes n (%)               | 5 (26.32)          | 4 (26.67)                         | 18 (42.86)                             | 0.332   |
| Smoking history n (%)        | 4 (21.05)          | 3 (20)                            | 3 (7.14)                               | 0.225   |
| Alcohol history n (%)        | 10 (52.63)         | 3 (20)                            | 12 (28.57)                             | 0.089   |
| BMI                          | 23.30 ± 3.11       | 23.62 ± 4.80                      | 23.65 ± 3.84                           | 0.947   |
| Scr (μmol/L)                 | 851.61 ± 275.60    | 734.84 ± 152.88                   | 783.74 ± 204.99                        | 0.079   |
| UA (mmol/L)                  | 407.85 ± 157.57    | 432.41 ± 101.99                   | 414.78 ± 108.57                        | 0.780   |
| BUN (mmol/L)                 | 25.76 ± 6.21       | 20.16 ± 7.94                      | 25.31 ± 7.80                           | 0.054   |
| ALB (g)                      | 42.59 ± 3.94       | 44.55 ± 11.21                     | 42.51 ± 3.70                           | 0.508   |
| Cholesterol (mmol/L)         | 4.28 ± 1.18        | 4.17 ± 1.10                       | 3.98 ± 1.04                            | 0.581   |
| Triglyceride (mmol/L)        | 2.12 ± 1.06        | 1.81 ± 0.75                       | 1.69 ± 0.57                            | 0.115   |
| HDL (mmol/L)                 | 1.84 ± 0.97        | 1.78 ± 0.54                       | 1.73 ± 0.40                            | 0.354   |
| LDL (mmol/L)                 | 2.32 ± 0.66        | 1.96 ± 0.79                       | 2.18 ± 0.34                            | 0.225   |
| Calcium (mmol/L)             | 2.19 ± 0.39        | 2.16 ± 0.32                       | 2.16 ± 0.26                            | 0.956   |
| Phosphorus (mmol/L)          | 2.12 ± 0.46        | 1.74 ± 0.41                       | 2.19 ± 0.92                            | 0.113   |
| WBC (10³/L)                  | 6.92 ± 1.65        | 6.90 ± 2.62                       | 7.12 ± 1.54                            | 0.882   |
| Hb (g/L)                     | 119.53 ± 15.71     | 126.17 ± 23.57                    | 115.68 ± 18.01                         | 0.179   |
| iPTH (pg/mL)                 | 551.57 ± 86.05     | 666.22 ± 300.89                   | 594.69 ± 22.08                         | 0.140   |
| Ferritin (ng/mL)             | 156.48 ± 26.60     | 167.05 ± 44.09                    | 165.53 ± 23.30                         | 0.471   |
| hs-CRP (mg/L)                | 14.80 ± 4.50       | 6.61 ± 3.41                       | 3.57 ± 1.42                            | 0.000   |
| Venous intimal thickness, μm (by ultrasound) | 26.54 ± 14.73 | 15.77 ± 4.32 | 14.89 ± 9.65 | 0.001 |
| Venous medial thickness, μm (by ultrasound) | 246.09 ± 53.78 | 134.74 ± 24.15 | 104.14 ± 29.32 | 0.000 |
| Serum Gal-3 (ng/ml)          | 3.73 ± 1.46        | 2.78 ± 0.43                       | 2.52 ± 1.51                            | 0.01    |

Data of clinical variables and demographic characteristics were expressed as the mean ± SD. Statistical comparisons were performed by chi-squared test or one way ANOVA. Differences with p < 0.05 were considered to be significant. *Duration of dialysis was equal to the duration of diagnosis of ESRD.
of experiments (IHC and western blotting) were expressed as the mean ± standard error of the mean (SEM). Statistical comparisons were performed by chi-squared test, or one-way ANOVA. Associations between IHC expression of Gal-3 and the IHC expression of PCNA or α-SMA, and between serum Gal-3 level and duration of hemodialysis were tested by using Pearson's correlation coefficients. Differences with \( p < 0.05 \) were considered to be significant.

Results

Demographic data and clinical variables of the involved patients

A total of 76 patients were recruited in this study (Figure 1). Nineteen cases were the patients (Stenosis AVF group) who received surgery revision due to AVF stenosis after hemodialysis via an AVF (PSV of stenotic AVF: 274.12 ± 105.55 cm/Sec) for 21.22 ± 9.73 months. Both the stenotic venous tissues and adjacent non-stenotic venous tissues (2 cm upstream of stenotic site) were collected during the surgical revision. Stenotic vein was proved in pathology. Fourty-two cases of controls (pre-AVF surgery group, normal control) were the normal vein samples that were collected from the patients who received AVF surgery for the first time, and the samples were collected before the AVF creation surgery. Besides, 15 ESRD patients (nonstenosis functional AVF group) who received hemodialysis through functional AVF were involved.

No statistical differences were observed in demographic data and in baseline clinical variables among these three groups, regarding age, gender, BMI, serum biochemistry, previous history (smoking status, diabetes, alcohol history, and hypertension history), except data showing that the mean duration of dialysis of patients with stenosis was higher than the other groups. And the
levels of hs-CRP were significantly higher in patients with AVF stenosis, compared to that in normal controls or non-stenosis functional AVF (Table 1).

Besides, we evaluated the serum levels of Gal-3 in involved patients, and we found that the levels of Gal-3 were significantly higher in patients with AVF stenosis, compared to that in normal controls or non-stenosis functional AVF (Table 1). Besides, in the stenosis AVF group, our data did not show the relation between serum Gal-3 level and duration of hemodialysis ($p = 0.780$).

**Expression of gal-3, α-SMA, MMP-9, and PCNA in stenotic AVF venous tissues**

The venous tissues of both groups (Stenosis AVF group and normal control group) were collected and stained with H&E. There is no increased thickness of the intima observed in normal vein of the control group (Figure 2). However, in the stenotic AVF venous tissues, histology investigation showed the cavity narrowing, intimal hyperplasia, neointima development, with extracellular matrix with admixed α-SMA positive mesenchymal cells (Figure 2). Moreover, the inflammatory cell infiltration was observed in the neointima. However, we did not observe the accumulations of foam cells or lipid cores characteristic of atherosclerosis. In media layer of the stenotic AVF venous tissues, we found prominent collagen aggregates (Figure 3(A)). Besides, calcification was commonly identified within the intima, media, and adventitia in stenotic AVF vessel samples (Figure 3(B)).

Different antibodies against Gal-3, α-SMA, MMP-9, and PCNA were then applied to investigate the expression of protein, respectively, in the vein samples (Figure 2). The results showed that the level of Gal-3 in the stenotic venous was increased, which was significantly higher than that in the adjacent non-stenotic venous tissues in intimal, medial, and adventitia layers of venous tissues, and there is merely an expression of Gal-3 in the normal venous intima.

PCNA is a nuclear nonhistone protein that is elevated during the G1/S phase of the cell cycle, which is necessary for DNA synthesis. PCNA expression may be used as a marker of cell proliferation because cells remain longer in the G1/S phase when proliferating. The expression of PCNA was increased in the intimal layer of stenotic AVF venous tissues, compared to the adjacent non-stenotic AVF venous tissues or normal venous tissues. Furthermore, the majority of cells composing the venous neointimal hyperplasia are α-SMA-positive myofibroblasts, and we investigated the expression of α-SMA in stenotic venous tissues. The expression level of α-SMA density was higher in the intimal layer of stenotic venous tissues compared to the group of adjacent non-stenotic venous tissues or the normal venous tissues. Besides, we found that the MMP-9 expression was increased in the intimal, medial, and adventitia layers of stenotic venous tissues, compared to that in adjacent non-stenotic venous tissues or the normal venous tissues.

Besides, using correlational analysis, we investigated the relationship between Gal-3 and PCNA or α-SMA in the neointima of stenotic AVF venous tissues, and the data showed positive correlation between Gal-3 and the expression of PCNA (coefficient, 0.59; $p < 0.01$) and α-SMA (coefficient, 0.46; $p < 0.05$) within the neointima.

Thereafter, we determined the ERK1/2 pathway activity in venous tissues by western blot, and we found that the phosphorylated ERK1/2 level and MEK level were both increased in stenotic AVF venous tissues, which was higher than that in adjacent non-stenotic AVF venous tissues or normal venous tissues (Figure 4).

**Gal-3 promotes expression of α-SMA via activation of the ERK1/2 pathway in SMCs**

It is known that the activation of the ERK1/2 pathway in SMCs contributes to AVF stenosis [22]. Thus, we investigated whether Gal-3 can activate ERK1/2 pathway in SMCs. The SMCs were cultured in vitro and treated with Gal-3, and the data showed that Gal-3 treatment can...
promote phosphorylated level of ERK1/2 (Figure 5(A,B)). Additionally, blocking ERK1/2 activity can clearly inhibit the expression of \(\alpha\)-SMA, and our data showed that Gal-3 can clearly promote the expression of \(\alpha\)-SMA in SMCs, which can be attenuated by an ERK1/2 inhibitor (Figure 5(A,C)).

**Discussion**

In this study, our results demonstrated the increased Gal-3 level in neointima of stenotic venous tissues of AVF, accompanied with upregulated expression of PCNA, MMP-9, and \(\alpha\)-SMA. Therefore, Gal-3 may contribute the development of the neointima.

It is well known that Gal-3 is expressed in the vascular smooth muscle cells and participates in the regulation of physiological and pathological functions of the vascular smooth muscle cells. Fort-Gallifa et al. found that Gal-3 expression is located in the intima and the media of arteries, which expression was significantly increased in peripheral artery disease [23]. Barman et al. [24] found that Gal-3 is expressed in the SMCs of pulmonary artery. In our study, we found that Gal-3 expression was clearly increased in the stenotic venous tissues, mainly located in both intimal and medial layers of the venous tissue, and then the increased Gal-3 expression might contribute to the development of AVF. Gal-3 can stimulate proliferation and migration of SMCs, while blocking Gal-3 attenuated remodeling and fibrosis of pulmonary artery in pulmonary hypertension [24]. Zhang et al. [25] suggested that hypoxia-induced Gal-3 expressed in intima and then triggered morphology transformation of endothelial into SMC features. Besides, Gal-3 has involved the vascular endothelial growth factor (VEGF) pathway [26–28], which was known to play an important role in the AVF stenosis pathology. In addition, we found the Gal-3 expression level was increased in the vessel samples from the 2 cm
upstream of stenotic vessels, we speculated the increased expression of Gal-3 might be attributed to the change hemodynamics of vessel, or the inflammatory response by stenosis. According to previous studies, both inflammation and hypertension would induce changes on intima, and gene expression [17,29–31].

During vein remodeling of AVF, histology changes were observed in all three layers of the venous wall, and these structural changes in endothelial and adventitial cells result in the maturation of AVF. However, excess alternation of structures of the venous wall would trigger stenosis development, in which one feature is the development of the neointima. Neointimal hyperplasia is composed of matrix proteins and proliferative and secretive cells. In our study, we observed the increased cell proliferation activity in stenotic AVF venous tissues, and we also found that the expression of a myofibroblast marker, α-SMA, was

**Figure 5.** Treatment of Gal-3 increases the activity of ERK1/2 pathway and expression of α-SMA in SMCs. The cells were cultured in vitro and were then treated with different reagents including Gal-3 and ERK1/2 inhibitor and then continued to culture for 72 h. Thereafter, cells were collected, and total proteins were extracted from cell pellets. The protein expression was examined using Western blot. (A) The representative images were shown with the analysis results. (B, C) The results showed that Gal-3 treatment significantly increased phosphorylated level of the ERK1/2 pathway and expression of α-SMA in SMCs, which can be alleviated by the ERK1/2 inhibitor. The ERK1/2 inhibitor can decrease the expression level of α-SMA. Data are presented as mean ± SEM (*p < 0.05; #p < 0.01, by one-way ANOVA).
increased in the intimal layer of AVF venous tissues. Researchers believe that SMCs of the medial and adventitia layer differentiate into myofibroblasts, migrate into the intima, and proliferate to contribute to the development of the neointima [28,32]. Moreover, myofibroblasts promote the formation of matrix bundles of contractile microfilaments and secrete matrix metalloproteinases [33,34], collagen, and ECM proteins to strengthen the fistula wall [35,36]. Some studies have addressed the effect of Gal-3 in myofibroblast. McLeod et al. found that Gal-3 induced the fibroblast to myofibroblast transition [37], while Henderson et al. found that Gal-3 is required for TGF-β-mediated hepatic stellate cell activation to a myofibroblast phenotype [38]. In the pathology of AVF, the increased Gal-3 could promote the myofibroblast phenotype transformation from SMCs of the medial/adventitia layer in the AVF by upregulation of α-SMA expression [39]. Moreover, increased Gal-3 expression stimulated migration and resistance to apoptosis in SMCs, while knockout Gal-3 reduced cellular migration and increased apoptosis [24]. However, conversely, Kim et al. suggested that in macrophages, the activated ERK1/2 pathway triggered the generation of Gal-3 [40], which may indicate the cell-type-associated specificity of the relationship between Gal-3 and ERK1/2 pathway. This might indicate that the generation of Gal-3 originated from both SMCs and macrophage in the neointima, in turn resulting in the increased serum Gal-3 level in patients with stenotic AVF. Moreover, the generation of Gal-3 by macrophages might facilitate the neointima pathology, which needs further research.

In previous, Gao et al. demonstrated that Gal-3 induced cell migration via activation of ERK1/2 pathway [41]. And it is known that the activation of ERK1/2 could play a key role in the development of AVF stenosis by promoting the proliferation and migration of SMCs [42]. As one of the important pro-inflammation factors, Gal-3 can activate ERK1/2 pathway, which in turn can regulate various downstream molecules, such as MMP-9 [43,44]. In our study, we observed the increased expression of MMP-9 in the stenotic venous tissues. It is well known that MMP-9 is a downstream molecular of ERK1/2 pathway [45]. The increased expression of MMP-9 in stenotic AVF pathology has been reported by multiple studies, including human and animal model [44,46–48]. In human patients, the patients with matured AVF had higher serum MMP-9 level [44,48], which indicated the MMP-9 was associated in vascular remodeling. In animal model, researchers found the increased expression of MMP-9 in AVF venous tissues [46,47]. And further study revealed that MMP-9 expression might contribute to myofibroblasts transdifferentiation of adventitial fibroblast [49]. In contrast, Rajiv et al. suggested that inhibition of MMP-9 level was related to the maturation of AVF in mice model [50]. Therefore, we speculated that Gal-3 might activate ERK1/2 pathway in SMCs and then promote cell proliferation, migration, and eventually the development of the neointima.

In addition, this study suffers from some limitations. We did not involve the animal model in this study, which could explore the outcome of Gal-3 inhibitor application to prevent stenosis development. Based on one study by Mackinnon et al., the administration of Gal-3 inhibitor TD139 in mice reduces the pathology of lung fibrosis [51] by inhibition of the SMC proliferation and migration.

In conclusion, our study demonstrated the increased generation of Gal-3 in the stenotic AVF, which then contributed to neointima development. The regulatory effect of Gal-3 on AVF could be through the ERK1/2 pathway. Therefore, blocking Gal-3 generation might attenuate stenosis development in AVF as a therapy strategy.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Innovative Research Program of Hebei University of Chinese Medicine (XCXZBS2019005).

ORCID

Xiaoguang Yao (http://orcid.org/0000-0003-4307-5777)

References

[1] Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–1982.
[2] Lok CE, H TS, Lee T, Shenoy S, National Kidney Foundation, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Practice Guidelines. 2020;75(4):164.
[3] Bae E, Lee H, Kim DK, et al. Autologous arteriovenous fistula is associated with superior outcomes in elderly hemodialysis patients. BMC Nephrol. 2018;19(1):306.
[4] Rooijens PP, Tordoir JH, Stijnen T, et al. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg. 2004;28(6):583–589.
[5] Roy-Chaudhury P, Kelly BS, Zhang J, et al. Hemodialysis vascular access dysfunction: from
pathophysiology to novel therapies. Blood Purif. 2003; 21(1):99–110.

[6] Rotmans JI, Pasterkamp G, Verhagen HJ, et al. Hemodialysis access graft failure: time to revisit an unmet clinical need? J Nephrol. 2005;18(1):9–20.

[7] Brahmbhatt A, Remuzzi A, Franzoni M, et al. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016;89(2):303–316.

[8] Marrone D, Pertosa G, Simone S, et al. Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis. 2007;49(5):664–673.

[9] Weiss MF, Scivittaro V, Anderson JM. Oxidative stress protects cells against galectin-3-induced apoptosis. J Biol Chem. 2008;283(32):22177–22185.

[10] Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl). 1996;74(10): 589–607.

[11] Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018;41(2):153–183.

[12] Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in molecular mechanisms of hemodialysis vascular access remodeling. Cell Physiol Biochem. 2017;51(2):763–777.

[13] Brahmbhatt A, Remuzzi A, Franzoni M, et al. The genetic basis for altered blood vessel anatomy, physiology, and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970–980.

[14] Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2): 11000.

[15] MacAskill MG, Watson DG, Ewart MA, et al. Improving arteriovenous fistula patency: Transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation. Vascul Pharmacol. 2015;71:108–115.

[16] Fort-Gallifa I, Hernandez-Aguilera A, Garcia-Heredia A, et al. Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation. Int J Mol Sci. 2017;18(5): 973.

[17] Barman SA, Li X, Haigh S, et al. Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019;316(5):L784–L797.

[18] Zhang L, Li YM, Zeng XX, et al. Galectin-3-mediated transdifferentiation of pulmonary artery endothelial cells contributes to hypoxic pulmonary vascular remodeling. Cell Physiol Biochem. 2018;51(2):763–777.

[19] Roy-Chaudhury P, Wang Y, Krishnamoorthy M, et al. Venous stenosis in a pig arteriovenous fistula model. J Vasc Interv Radiol. 2010;21(8):1255–1261.

[20] Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S): 135–245.

[21] Agrotis A. The genetic basis for altered blood vessel function in disease: large artery stiffening. Vasc Health Risk Manag. 2005;1(4):333–344.

[22] Rowan MA, Shalhub J, Lim CS, et al. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression. J Vasc Res. 2012;49(6): 463–478.

[23] Sagaghiannou N, Contetti J, Dardik A, et al. Role of hypoxia and metabolism in the development of neointimal hyperplasia in arteriovenous fistulas. Int J Mol Sci. 2019;20(21): 5387.

[24] Misra S, Doherty MG, Woodrum D, et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int. 2005;68(6):2890–2900.

[25] Misra S, Shergill U, Yang B, et al. Increased expression of HIF-1alpha, VEGF-A and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency. J Vasc Interv Radiol. 2010;21(8):1255–1261.

[26] Wang Y, Krishnamoorthy M, Banerjee R, et al. Venous stenosis in a pig arteriovenous fistula model–anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant. 2007;23(2):525–533.
haemodialysis vascular access. Nephrol Dial Transplant. 2009;24(9):2786–2791.

[37] McLeod K, Walker JT, Hamilton DW. Galectin-3 regulation of wound healing and fibrotic processes: insights for chronic skin wound therapeutics. J Cell Commun Signal. 2018;12(1):281–287.

[38] Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103(13):5060–5065.

[39] Chen WS, Cao Z, Leffler H, et al. Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis. Invest Ophthamol Vis Sci. 2017;58(1):9–20.

[40] Kim K, Mayer EP, Nachtigal M. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta. 2003;1641(1):13–23.

[41] Gao X, Balan V, Tai G, et al. Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. 2014;5(8):2077–2084.

[42] Wan J, Lata C, Santilli A, et al. Supplemental oxygen reverses hypoxia-induced smooth muscle cell proliferation by modulating HIF-alpha and VEGF levels in a rabbit arteriovenous fistula model. Ann Vasc Surg. 2014;28(3):725–736.

[43] Dange MC, Agarwal AK, Kalraiya RD. Extracellular galectin-3 induces MMP9 expression by activating p38 MAPK pathway via lysosome-associated membrane protein-1 (LAMP1). Mol Cell Biochem. 2015;404(1-2):79–86.

[44] Lee ES, Shen Q, Pitts RL, et al. Serum metalloproteinases MMP-2, MMP-9, and m7etalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation. J Vasc Surg. 2011;54(2):454–459. discussion 459–460.

[45] Xiao L, Lin P, Lin F, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell cancer cell invasion. Int J Oncol. 2012;40(5):1714–1724.

[46] Yang B, Shergill U, Fu AA, et al. The mouse arteriovenous fistula model. J Vasc Inter Radiol. 2009;20(7):946–950.

[47] Misra S, Fu AA, Anderson JL, et al. The rat femoral arteriovenous fistula model: increased expression of matrix metalloproteinase-2 and -9 at the venous stenosis. J Vasc Inter Radiol. 2008;19(4):587–594.

[48] Lee ES, Shen Q, Pitts RL, et al. Vein tissue expression of matrix metalloproteinase as biomarker for hemodialysis arteriovenous fistula maturation. Vasc Endovascular Surg. 2010;44(8):674–679.

[49] Sartore S, Chiavegato A, Faggin E, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89(12):1111–1121.

[50] Janardhanan R, Yang B, Vohra P, et al. Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int. 2013;84(2):338–352.

[51] Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537–546.